Deep Venous Thrombosis, Pulmonary Embolism
Conditions
Keywords
dabigatran, warfarin, apixaban, edoxaban, extended treatment, oral anticoagulant, rivaroxaban, comparative safety, comparative effectiveness
Brief summary
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Since 2010, four new oral anticoagulants have been approved for marketing in addition to the vitamin K antagonist warfarin. Very limited head-to-head data exists comparing these treatment options, leaving patients, clinicians, and other stakeholders with little guidance for selecting the best strategy that balances recurrence reduction with risk of bleeding. In the DARE Warfarin CER Study, the researchers compare all five currently available oral anticoagulant agents for the extended treatment of DVT and PE, as well as no extended treatment. This study also aims to evaluate whether treatment heterogeneity exists for specific populations, such as older patients or those with renal dysfunction. In a secondary aim, the study will also leverage a database of linked electronic health record-insurance claims to validate diagnosis definitions and account for potential residual confounding by factors unmeasured in claims data. As the patient population includes all Medicare novel anticoagulant users and large numbers of commercially insured and Medicaid patients, the results will likely be transportable to the majority of US patients experiencing a DVT or PE. Pursuant to the objectives of the Patient-Centered Outcomes Research Institute, a study advisory committee consisting of key stakeholders will be actively involved in the study design and dissemination of results.
Interventions
DRUGDabigatran: extended treatment (e.g at least 90 days)
90 days
DRUGDabigatran: extended treatment (e.g at least 180 days)
180 days
DRUGDabigatran: extended treatment (e.g at least 270 days)
270 days
DRUGApixaban: extended treatment (e.g at least 90 days)
90 days
DRUGApixaban: extended treatment (e.g at least 180 days)
180 days
DRUGApixaban: extended treatment (e.g at least 270 days)
270 days
DRUGRivaroxaban: extended treatment (e.g at least 90 days)
90 days
DRUGRivaroxaban: extended treatment (e.g at least 180 days)
180 days
DRUGRivaroxaban: extended treatment (e.g at least 270 days)
270 days
DRUGEdoxaban: extended treatment (e.g at least 90 days)
90 days
DRUGEdoxaban: extended treatment (e.g at least 180 days)
180 days
DRUGEdoxaban: extended treatment (e.g at least 270 days)
270 days
DRUGWarfarin: extended treatment (e.g at least 90 days)
90 days
DRUGWarfarin: extended treatment (e.g at least 180 days)
180 days
DRUGWarfarin: extended treatment (e.g at least 270 days)
270 days
Sponsors
Harvard Medical School (HMS and HSDM)
Patient-Centered Outcomes Research Institute
Brigham and Women's Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Inpatient stay with diagnosis code of DVT/PE (see Appendix A), 1/1/2010 - 9/30/2015 for which the patient has at least 365 days continuous medical and pharmacy eligibility prior and no other inpatient stays with DVT/PE diagnosis. Set discharge date as index diagnosis date. Take only the first eligible episode for a patient, if multiple. 2. Prescription fill for an anticoagulant \[generic name=dabigatran (150mg), apixaban (2.5mg, 5mg, 10mg), rivaroxaban (15mg, 20mg), edoxaban (30mg, 60mg), or warfarin\] within 30 days of and including index diagnosis date. Set earliest anticoagulant prescription as index generic and date as index rx date. 3. No anticoagulant prescription fill in the 365 days prior to index diagnosis date. 4. Continuous enrollment and use of an anticoagulant for the first 90 days including and following the index rx date, defined as no gaps in therapy \>7 days. For each patient, assign a variable to indicate whether the patient filled an anticoagulant with a different generic name as index during this period.
Exclusion criteria
1. Any safety outcome between index diagnosis date and index rx date + 90, defined as: intracranial bleed, gastrointestinal bleed, or other major bleed. 2. Any DVT/PE between index diagnosis date and index rx date + 90.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite Safety Outcome: Intracranial bleed, Gastrointestinal bleed, Other Major bleed | 1-2 Years | Defined as a new episode of either Intracranial bleed, Gastrointestinal bleed or another Major bleed event during follow-up. |
| Composite Effectiveness Outcome: Deep Venous Thrombosis, Pulmonary Embolism | 1-2 Years | Defined as a new episode of either Deep Venous Thrombosis or Pulmonary Embolism during follow-up. |
| Death | 1-2 Years | Measured after index prescription date + 90 days and on date on which the event occurred and defined as hospitalization with discharge status code of: 20, 22-29, 40-42 |
| Composite safety and effectiveness outcome | 1-2 years | defined as earlier of safety or DVT/PE outcomes |
| Composite safety and effectiveness outcome, including death | 1-2 years | Measured after index prescription date + 90 days and on date on which the event occurred and defined as hospitalization with discharge status code of: 20, 22-29, 40-42 |
Countries
United States
Outcome results
None listed